OLMA NASDAQ
Olema Pharmaceuticals, Inc.
1W: -2.9%
1M: -18.2%
3M: -37.1%
YTD: -72.2%
1Y: -12.3%
3Y: -33.5%
5Y: -73.7%
$7.04
+0.42 (+6.34%)
Weekly Expected Move ±7.9%
$5
$6
$6
$7
$7
Credit Risk of going bust: lower than 54% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Olema Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $660K against a stock market value of $579.2M.
Distance to default 5.54 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $660K (short-term plus half of long-term), stock volatility 111.9%; Altman Z'' 6.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Olema Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $660K against a stock market value of $579.2M.
Distance to default 5.54 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $660K (short-term plus half of long-term), stock volatility 111.9%; Altman Z'' 6.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (62)
Olema Pharmaceuticals (NASDAQ:OLMA) Hits New 52-Week Low – Time to Sell?
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Bank of America Corp DE Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA
Olema drops after hours on AstraZeneca Etcamah data
66,163 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Connor Clark & Lunn Investment Management Ltd.
HC Wainwright Issues Pessimistic Estimate for OLMA Earnings
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
SG Americas Securities LLC Purchases Shares of 69,382 Olema Pharmaceuticals, Inc. $OLMA
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Moderate Buy” from Analysts
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
HC Wainwright Analysts Raise Earnings Estimates for OLMA
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 5.2% Following Analyst Downgrade
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Pharmaceuticals (NASDAQ:OLMA) Trading 8.5% Higher After Strong Earnings
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Olema Pharmaceuticals GAAP EPS of -$0.50 beats by $0.01
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
HC Wainwright Has Negative Estimate for OLMA FY2029 Earnings
What's Going On With Olema Pharmaceuticals Stock On Wednesday?
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down Following Analyst Downgrade
12 Health Care Stocks Moving In Monday's Intraday Session
Why Is Olema Pharmaceuticals Stock Dropping On Monday?
Dow Tumbles Over 600 Points; Korn Ferry Posts Upbeat Earnings
12 Health Care Stocks Moving In Monday's Pre-Market Session
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Moderate Buy” from Analysts
Invesco BulletShares 2032 Municipal Bond ETF declares monthly distribution of $0.0658
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit
Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Announces Departure of Chief Operating and Financial Officer
Campbell & CO Investment Adviser LLC Buys New Shares in Olema Pharmaceuticals, Inc. $OLMA
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 3,489 Shares
Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Moderate Buy” from Brokerages
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells $82,194.93 in Stock
David Myles Sells 51,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Naseem Zojwalla Sells 70,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Ian Clark Sells 264,800 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Naseem Zojwalla Sells 99,509 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Naseem Zojwalla Sells 100,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Olema Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:OLMA)